Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Moxetumomab Pasudotox for the Treatment of Hairy Cell Leukaemia

Drug Name

Moxetumomab pasudotox

Developer

Medimmune

Therapy Class

Immunotoxin

Product Description

Investigational anti-CD22 recombinant immunotoxin

Current Indication

Hairy cell leukaemia

Market Sector

Oncology

Development Status

Phase three
Expand

Go Top